This section is primarily intended for SARS-CoV-2 test developers. For general public and consumer FAQs on COVID-19, please see FDA’s COVID-19 Frequently Asked Questions.
This section provides answers to frequently asked questions relating to the development and performance of tests for SARS-CoV-2. These questions and answers provide additional clarity on existing policies and do not introduce any new policies or modify any existing policies.
See more: Covid 19 q&a ncaa
View more: Update: Hawthorne-based SpaceX’s astronauts splash down safely after trek home from space station
This section includes questions and answers regarding the policies described in the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised), originally issued as Policy for Diagnostic Tests in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency on February 29, 2020 and updated on March 16, 2020, May 4, 2020, May 11, 2020, and November 15, 2021. In this section, this guidance is referred to as the Policy for Coronavirus Disease-2019 Tests.
Tests being offered prior to or without an EUA as described in a policy in a previous version or the current version of the Policy for Coronavirus Disease-2019 Tests have not been reviewed or authorized by the FDA. As stated in the current and previous versions of the Policy for Coronavirus Disease-2019 Tests, all such tests should be validated by the developer prior to being offered for clinical use.
View more: Build a custom email digest by following topics, people, and firms published on JD Supra
Note: Throughout this section and the Policy for Coronavirus Disease-2019 Tests, references to laboratories that are “certified to perform high complexity testing under CLIA” or to “high-complexity CLIA-certified laboratories” are referring to CLIA-certified laboratories that meet the regulatory requirements to perform high-complexity testing.
Get Updates: In Vitro Diagnostics
The FDA intends to update the sections of this page regularly. Sign up for email alerts.
Email Address Subscribe
Pages in this section:
- Notifications and Emergency Use Authorizations
- At-Home COVID-19 Diagnostic Tests
- Test Development and Review
- Test Uses
- Testing Supplies
- COVID-19 Related Test Data and Reporting
COVID-19 Resources for Test Developers
- Emergency Use Authorizations for Medical Devices: Includes EUAs for In Vitro Diagnostics (e.g., molecular, antigen, and serology tests)
- Coronavirus (COVID-19) and Medical Devices: In Vitro Diagnostic Tests
- SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests
- FAQs on Viral Transport Media During COVID-19: Includes questions and answers regarding the policies outlined in the Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.
- EUA Authorized Serology Test Performance
- Independent Evaluations of COVID-19 Serological Tests
- SARS-CoV-2 Reference Panel Comparative Data
- Pooled Sample Testing and Screening Testing for COVID-19
- Virtual Town Hall Series – Coronavirus (COVID-19) Test Development and Validation
Reporting Problems to the FDA
The sale of fraudulent COVID-19 products is a threat to the public health. Consumers and health care professionals can help by reporting suspected fraud to the FDA’s Health Fraud Program or the Office of Criminal Investigations. You can also email FDA-COVID-19-Fraudulent-Products@fda.hhs.gov. If you are a health professional, consumer or patient and think you had a problem with your diagnostic test, the FDA encourages you to report the problem through the MedWatch Voluntary Reporting Form. Health care personnel employed by facilities performing COVID-19 testing should follow the reporting procedures established by their facilities.
